Two Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition


PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect, are among the seven breakthrough medical solutions from around the world competing for the Disruptive Technology Award 2019 granted by the American Association for Clinical Chemistry (AACC), the world’s largest organization which brings together medical diagnostic specialists.

Shortlisting both Scope Fluidics’ projects in a very small group of semi-finalists guarantees them presentation of PCR|ONE and BacterOMIC systems at their own stands in the AACC’s Innovation Zone during the 71st edition of the AACC Annual Scientific Meeting, the world’s largest diagnostic fair and conference. The AACC conference and fair is attended by over 20 thousand representatives of companies and diagnostic laboratories. AACC itself brings together 50,000 medical diagnostic professionals, physicians, scientists, and diagnostic company leaders from around the world to develop medical diagnostic methods – molecular diagnostics, clinical chemistry, mass spectrometry, and precision medicine. AACC is also the publisher of Clinical Chemistry, the most important scientific periodical in the field of medical diagnostics.

Qualifying for the semi-final is a great honour for our projects. The most ground-breaking diagnostic technologies from all over the world are submitted to the competition. I am proud that our projects have been recognized and distinguished by such a prestigious organization, – comments Prof. Piotr Garstecki, co-founder, key shareholder and CEO of Scope Fluidics.

The presence of both projects developed by Scope Fluidics in the semi-final of the competition confirms the pioneering and globally unprecedented nature of the technologies developed by the company.

Thanks to this, we will attract attention focused on modern solutions at the most important trade fair for medical diagnostics in the world. This will help us attract potential partners in the commercialization of PCR|ONE and BacterOMIC diagnostic systems – adds Szymon Ruta, CFO and Member of the Management Board of Scope Fluidics.

AACC Annual Scientific Meeting will be held between 5-8 of August in Anaheim, California. Scope Fluidics will present PCR|ONE, the world’s most rapid system for comprehensive detection of infections, and the BacterOMIC system that offers the most extensive information on the effectiveness of antibiotic therapies.

More information about the award: